Save Product
Product Details
Synonym
CTSB, CPSB, APPS
Source
Human Cathepsin B (18-339) Protein, His Tag (CTB-H52H3) is expressed from human 293 cells (HEK293). It contains AA Arg 18 - Ile 339 (Accession # P07858-1).
Predicted N-terminus: Arg 18
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 37.8 kDa. The protein migrates as 40-43 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Supplied as 0.2 μm filtered solution in 50 mM NaAc, 2 M NaCl, pH5.0 with glycerol as protectant.
Contact us for customized product form or formulation.
Shipping
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Storage
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human Cathepsin B (18-339) Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Human Cathepsin B (18-339) Protein, His Tag (Cat. No. CTB-H52H3) is more than 90% and the molecular weight of this protein is around 30-45 kDa verified by SEC-MALS.
Report
Bioactivity
Measured by its ability to cleave the fluorogenic peptide substrate Z-LR-AMC. The specific activity is >3,500 pmol/min/µg (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Cathepsin B
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
2 Details
- Highest Development Stage：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
